Management of Pyrexia of Unknown Origin
Initial Diagnostic Approach
- Obtain comprehensive blood cultures before initiating any antimicrobial therapy, as recommended by the American College of Physicians, to identify the cause of fever in patients with pyrexia of unknown origin 1
- Complete blood count with differential should be performed to monitor trends and assess for neutropenia in patients with pyrexia of unknown origin, according to the American College of Physicians 1
- Determine severity of neutropenia based on absolute neutrophil count (ANC): Mild (ANC 1.0-1.5 × 10^9/L), Moderate (ANC 0.5-1.0 × 10^9/L), Severe (ANC < 0.5 × 10^9/L), as defined by the American College of Physicians 1
- Chest imaging, such as X-rays or CT scans, should be performed for patients with respiratory symptoms or persistent fever, as recommended by the American College of Radiology 2
Management Algorithm Based on PUO Type
- For severe neutropenia (ANC < 0.5 × 10^9/L) with fever, the American College of Physicians recommends initiating broad-spectrum antibacterial therapy immediately 1
- For low-risk patients with no identified cause and ANC ≥ 0.5 × 10^9/L at 48 hours, the European Society for Medical Oncology suggests considering changing to oral antibiotics 3
- For high-risk patients with no identified cause and ANC ≥ 0.5 × 10^9/L at 48 hours, the European Society for Medical Oncology recommends that if on dual therapy, aminoglycoside may be discontinued 3
- For patients with persistent fever >4-6 days, the European Society for Medical Oncology suggests considering initiating antifungal therapy 3
- The American College of Radiology recommends considering FDG-PET/CT for localization of infection source, particularly in immunosuppressed patients 2
Advanced Diagnostic Strategies
- The American College of Radiology recommends considering FDG-PET/CT for patients with prolonged unexplained fever, which has shown high sensitivity and specificity for detecting infections and inflammatory processes 2
- For suspected invasive fungal disease, the European Society for Medical Oncology recommends performing high-resolution chest CT promptly, looking for typical features such as nodules with haloes or ground-glass changes 3
- If fungal infection is suspected and infiltrates are found on imaging, the European Society for Medical Oncology suggests that bronchoalveolar lavage should be performed when possible 3
Empiric Therapy Considerations
- For suspected aspergillosis (based on CT findings), the European Society for Medical Oncology recommends using either voriconazole or liposomal amphotericin B 3
- For suspected viral encephalitis, the European Society for Medical Oncology suggests using high-dose aciclovir after appropriate samples are taken 3
- For suspected bacterial meningitis, the European Society for Medical Oncology recommends using ceftazidime plus ampicillin (to cover Listeria monocytogenes) or meropenem 3
Pitfalls and Caveats
- The American College of Physicians recommends not delaying antimicrobial therapy in febrile neutropenic patients while waiting for culture results 1
- The American College of Physicians suggests avoiding unnecessary antibiotic use in patients with recovered neutrophil counts who are afebrile and asymptomatic 1
Pyrexia of Unknown Origin (PUO): Management and Investigation
Medication-Induced Fever
- The National Comprehensive Cancer Network recommends considering drug-induced fever as a cause of pyrexia, particularly with BRAF inhibitors, which commonly cause pyrexia 2-4 weeks after initiation 4
- A detailed medication history is crucial to identify drug-induced causes, including immunosuppressants, BRAF inhibitors, and chemotherapy agents, as suggested by the American Thoracic Society 4, 5
Environmental Exposures
- The American Thoracic Society suggests documenting environmental exposures, including mold, birds, down feathers, animals, metal dusts, wood dust, livestock, and recent occupational changes, to aid in the diagnosis of PUO 5
Investigation Strategy
- Second-tier serological testing, including ANA, RF, anti-CCP antibodies, and others, may be necessary if connective tissue disease is suspected, as recommended by the American Thoracic Society 5